The Manufacturers Life Insurance Company Increases Stock Position in Evolus, Inc. (NASDAQ:EOLS)

The Manufacturers Life Insurance Company boosted its stake in Evolus, Inc. (NASDAQ:EOLS) by 36.3% during the 2nd quarter, Holdings Channel reports. The firm owned 21,825 shares of the company’s stock after buying an additional 5,808 shares during the quarter. The Manufacturers Life Insurance Company’s holdings in Evolus were worth $237,000 at the end of the most recent reporting period.

Several other hedge funds have also bought and sold shares of EOLS. Los Angeles Capital Management LLC purchased a new stake in Evolus in the 1st quarter worth $1,907,000. Principal Financial Group Inc. raised its position in shares of Evolus by 141.7% during the 1st quarter. Principal Financial Group Inc. now owns 34,785 shares of the company’s stock valued at $487,000 after buying an additional 20,391 shares in the last quarter. BNP Paribas Financial Markets raised its position in shares of Evolus by 84.2% during the 1st quarter. BNP Paribas Financial Markets now owns 405,931 shares of the company’s stock valued at $5,683,000 after buying an additional 185,532 shares in the last quarter. Essex Investment Management Co. LLC raised its position in shares of Evolus by 1.5% during the 1st quarter. Essex Investment Management Co. LLC now owns 254,811 shares of the company’s stock valued at $3,567,000 after buying an additional 3,761 shares in the last quarter. Finally, Swiss National Bank raised its position in shares of Evolus by 6.8% during the 1st quarter. Swiss National Bank now owns 95,900 shares of the company’s stock valued at $1,343,000 after buying an additional 6,100 shares in the last quarter. Hedge funds and other institutional investors own 90.69% of the company’s stock.

Evolus Stock Performance

Evolus stock opened at $16.62 on Friday. The company has a debt-to-equity ratio of 6.26, a current ratio of 2.92 and a quick ratio of 2.67. Evolus, Inc. has a 1-year low of $7.44 and a 1-year high of $17.82. The firm has a market capitalization of $1.04 billion, a P/E ratio of -15.85 and a beta of 1.31. The company’s 50-day moving average is $15.81 and its 200 day moving average is $13.46.

Evolus (NASDAQ:EOLS) last issued its earnings results on Wednesday, July 31st. The company reported ($0.14) EPS for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.02). The business had revenue of $66.91 million for the quarter, compared to analyst estimates of $65.06 million. Research analysts forecast that Evolus, Inc. will post -0.64 EPS for the current year.

Insiders Place Their Bets

In other Evolus news, CFO Sandra Beaver sold 3,276 shares of the company’s stock in a transaction dated Friday, September 6th. The shares were sold at an average price of $14.98, for a total value of $49,074.48. Following the transaction, the chief financial officer now directly owns 148,502 shares in the company, valued at $2,224,559.96. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In other Evolus news, CFO Sandra Beaver sold 3,276 shares of the company’s stock in a transaction dated Friday, September 6th. The shares were sold at an average price of $14.98, for a total value of $49,074.48. Following the transaction, the chief financial officer now directly owns 148,502 shares in the company, valued at $2,224,559.96. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CMO Tomoko Yamagishi-Dressler sold 5,631 shares of the company’s stock in a transaction dated Friday, August 30th. The stock was sold at an average price of $15.85, for a total transaction of $89,251.35. Following the completion of the transaction, the chief marketing officer now owns 82,375 shares in the company, valued at $1,305,643.75. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 6.10% of the company’s stock.

Analyst Ratings Changes

EOLS has been the topic of several recent research reports. HC Wainwright restated a “buy” rating and set a $27.00 target price on shares of Evolus in a research report on Thursday, October 3rd. Barclays upped their target price on shares of Evolus from $16.00 to $20.00 and gave the company an “overweight” rating in a research report on Friday, September 13th. Needham & Company LLC restated a “buy” rating and set a $22.00 target price on shares of Evolus in a research report on Friday, September 13th. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Evolus in a research report on Monday, September 16th.

Evolus Profile

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.